- Home
- PHAR vs PLRX Comparison
PHAR vs PLRX Comparison
Compare PHAR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PLRX
- Stock Information
- Founded
- PHAR 1988
- PLRX 2015
- Country
- PHAR Netherlands
- PLRX United States
- Employees
- PHAR N/A
- PLRX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- PLRX Health Care
- Exchange
- PHAR Nasdaq
- PLRX Nasdaq
- Market Cap
- PHAR 718.1M
- PLRX 84.7M
- IPO Year
- PHAR N/A
- PLRX 2020
- Fundamental
- Price
- PHAR $10.27
- PLRX $1.29
- Analyst Decision
- PHAR Strong Buy
- PLRX Hold
- Analyst Count
- PHAR 3
- PLRX 10
- Target Price
- PHAR $30.00
- PLRX $9.79
- AVG Volume (30 Days)
- PHAR 4.3K
- PLRX 1.5M
- Earning Date
- PHAR 07-31-2025
- PLRX 08-06-2025
- Dividend Yield
- PHAR N/A
- PLRX N/A
- EPS Growth
- PHAR N/A
- PLRX N/A
- EPS
- PHAR N/A
- PLRX N/A
- Revenue
- PHAR $320,708,000.00
- PLRX N/A
- Revenue This Year
- PHAR $13.31
- PLRX N/A
- Revenue Next Year
- PHAR $7.68
- PLRX N/A
- P/E Ratio
- PHAR N/A
- PLRX N/A
- Revenue Growth
- PHAR 24.13
- PLRX N/A
- 52 Week Low
- PHAR $6.65
- PLRX $1.10
- 52 Week High
- PHAR $12.61
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- PHAR 48.21
- PLRX 43.30
- Support Level
- PHAR $10.46
- PLRX $1.13
- Resistance Level
- PHAR $11.49
- PLRX $1.43
- Average True Range (ATR)
- PHAR 0.37
- PLRX 0.11
- MACD
- PHAR -0.12
- PLRX -0.01
- Stochastic Oscillator
- PHAR 27.62
- PLRX 37.57
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.